Advertisement

Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Howlader N.
        • Altekruse S.F.
        • Li C.I.
        • et al.
        US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
        J Natl Cancer Inst. 2014; 106: dju055
        • Burstein H.J.
        Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer.
        N Engl J Med. 2020; 383: 2557-2570
        • Early Breast Cancer Trialists’ Collaborative Group
        Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient level meta-analysis of randomised trials.
        Lancet. 2011; 378: 771-784
        • Giuliano A.E.
        • Edge S.B.
        • Hortobagyi G.N.
        Eighth edition of the AJCC Cancer staging manual: breast cancer.
        Ann Surg Oncol. 2018; 25: 1783-1785
        • Cardoso F.
        • Kyriakides S.
        • Ohno S.
        • et al.
        Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 1194-1220
        • Allison K.H.
        • Hammond M.E.
        • Dowsett M.
        • et al.
        Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update.
        J Clin Oncol. 2020; 38: 1346-1366
        • Paik S.
        • Shak S.
        • Tang G.
        • et al.
        A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
        N Engl J Med. 2004; 351: 2817-2826
        • Paik S.
        • Tang G.
        • Shak S.
        • et al.
        Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
        J Clin Oncol. 2006; 24: 3726-3734
        • Sparano J.A.
        • Gray R.J.
        • Makower D.F.
        • et al.
        Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.
        N Engl J Med. 2018; 379: 111-121
        • Sparano J.A.
        • Crager M.R.
        • Tang G.
        • et al.
        Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer.
        J Clin Oncol. 2021; 39: 557-564
        • Kalinsky K.
        • Barlow W.E.
        • Gralow J.R.
        • et al.
        21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
        N Eng J Med. 2021; 385: 2336-2347
        • Harbeck N.
        • Burstein H.J.
        • Hurvitz S.A.
        • et al.
        A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
        Cancer. 2022; 128: 2209-2223
        • Buyse M.
        • Loi S.
        • van't Veer L.
        • et al.
        Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
        J Natl Cancer Inst. 2006; 98: 1183-1192
        • Cardoso F.
        • van't Veer L.J.
        • Bogaerts J.
        • et al.
        for the MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer.
        N Engl J Med. 2016; 375: 717-729
        • Gnant M.
        • Sestak I.
        • Filipits M.
        • et al.
        Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
        Ann Oncol. 2015; 26: 1685-1691
        • Dowsett M.
        • Sestak I.
        • Lopez-Knowles E.
        • et al.
        Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
        J Clin Oncol. 2013; 31: 2783-2790
        • Sgroi D.C.
        • Sestak I.
        • Cuzick J.
        • et al.
        Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
        Lancet Oncol. 2013; 14: 1067-1076
        • Bartlett J.M.S.
        • Sgroi D.C.
        • Treuner K.
        • et al.
        Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
        Ann Oncol. 2019; 30: 1776-1783
        • National Comprehensive Cancer Network
        Breast cancer (version 7.2021).
        • Andre F.
        • Ismaila N.
        • Henry N.L.
        • et al.
        Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx.
        J Clin Oncol. 2019; 37: 1956-1964
        • Burstein H.J.
        • Curigliano G.
        • Thurlimann B.
        • et al.
        Customising local and systemic therapies for women with early breast cancer: the St Gallen International Consensus Guidelines for treatment of early breast cancer.
        Ann Oncol. 2021; 32: 1216-1235.021
        • Fisher B.
        • Bryant J.
        • Dignam J.J.
        • et al.
        Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
        J Clin Oncol. 2002; 20: 4141-4149
        • Harvey J.M.
        • Clark G.M.
        • Osborne C.K.
        • et al.
        Estrogen receptor status by immuno-histochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
        J Clin Oncol. 1999; 17: 1474-1481
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
        Lancet. 2015; 386: 1341-1352
        • Smith I.E.
        • Dowsett M.
        Aromatase inhibitors and breast cancer.
        N Engl J Med. 2003; 348: 2431-2442
        • Cusick J.
        • Sestak I.
        • Baum M.
        • et al.
        • on behalf of the ATAC/LATTE Investigators
        Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
        Lancet Oncol. 2010; 11: 1135-1141
        • Ruhstaller T.
        • Giobbie-Hurder A.
        • Colleoni M.
        • et al.
        for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial.
        J Clin Oncol. 2019; 37: 105-114
        • Viale G.
        • Regan M.M.
        • Dell’Orto P.
        • et al.
        Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
        Ann Oncol. 2011; 22: 2201-2207
        • Metzger Filho O.
        • Giobbie-Hurder A.
        • Mallon E.
        • et al.
        Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.
        J Clin Oncol. 2015; 33: 2772-2779
        • Chirgwin J.H.
        • Giobbie-Hurder A.
        • Coates A.S.
        • et al.
        Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence.
        J Clin Oncol. 2016; 34: 2452-2459
        • Gupta A.
        • Henry N.L.
        • Loprinzi C.L.
        Management of aromatase inhibitorinduced musculoskeletal symptoms.
        JCO Oncol Pract. 2020; 16: 733-739
        • Regan M.M.
        • Neven P.
        • Giobbie-Hurder A.
        • et al.
        Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
        Lancet Oncol. 2011; 12: 1101-1108
        • Colleoni M.
        • Luo W.
        • Karlsson P.
        • et al.
        on behalf of the SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 127-138
        • Pan H.
        • Gray R.
        • Braybrooke J.
        • et al.
        20- Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.
        N Engl J Med. 2017; 377: 1836-1846
        • Sestak I.
        • Dowsett M.
        • Zabaglo L.
        • et al.
        Factors predicting late recurrence for estrogen receptor-positive breast cancer.
        J Natl Cancer Inst. 2013; 105: 1504-1511
        • Burstein H.J.
        • Lacchetti C.
        • Anderson H.
        • et al.
        Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO Clinical Practice Guideline focused update.
        J Clin Oncol. 2019; 37: 423-438
        • Gnant M.
        • Fitzal F.
        • Rinnerthaler G.
        • et al.
        Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
        N Engl J Med. 2021; 385: 395-405
        • Gray R.
        • Early Breast Cancer Trialists' Collaborative Group
        Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women.
        Cancer Res. 2019; 79 (Abstract GS3-03)
        • Blum J.L.
        • Flynn P.J.
        • Yothers G.
        • et al.
        Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
        J Clin Oncol. 2017; 35: 2647-2655
        • Nitz U.
        • Gluz O.
        • Clemens M.
        • et al.
        behalf of the West German Study Group PlanB Investigators. West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer.
        J Clin Oncol. 2019; 37: 799-808
        • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
        Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
        Lancet. 2015; 386: 1353-1361
        • Harbeck N.
        • Penault-Llorca F.
        • Cortes J.
        • et al.
        Breast cancer.
        Nat Rev Dis Primers. 2019; 5: 66
        • Nelson D.R.
        • Brown J.
        • Morikawa A.
        • et al.
        Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
        PLoS ONE. 2022; 17 (Available at:): e0264637https://doi.org/10.1371/journal.pone.0264637
        • Spring L.M.
        • Wander S.A.
        • Andre F.
        • et al.
        Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
        Lancet. 2020; 395: 817-827
        • Mayer E.L.
        • Dueck A.C.
        • Martin M.
        • et al.
        Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
        Lancet Oncol. 2021; 22: 212-222
        • Gnant M.
        • Dueck A.C.
        • Frantal S.
        • et al.
        Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
        J Clin Oncol. 2022; 40: 282-293
        • Loibl S.
        • Marmé F.
        • Martin M.
        • et al.
        Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the Penelope-B trial.
        J Clin Oncol. 2021; 39: 1518-1530
        • Johnston S.R.D.
        • Harbeck N.
        • Hegg R.
        • et al.
        Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
        J Clin Oncol. 2020; 38: 3987-3998
        • Harbeck N.
        • Rastogi P.
        • Martin M.
        • et al.
        Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
        Ann Oncol. 2021; 32: 1571-1581
        • Royce M.
        • Osgood C.
        • Mulkey F.
        • et al.
        FDA Approval Summary: Abemaciclib with endocrine therapy for high-risk early breast cancer.
        J Clin Oncol. 2022; 40: 1155-1162
        • Giordano S.H.
        • Freedman R.A.
        • Somerfield M.R.
        • et al.
        Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update.
        J Clin Oncol. 2022; 40: 307-309
        • Dowsett M.
        Testing endocrine response for managing primary estrogen receptor-positive breast cancer.
        J Clin Oncol. 2022; 40: 2520-2523
        • Smith I.
        • Robertson J.
        • Kilburn L.
        • et al.
        Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multi-centre, parallel-group, randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1443-1454
        • Ellis M.J.
        • Suman V.J.
        • Hoog J.
        • et al.
        Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer; results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance.
        ) J Clin Oncol. 2017; 35: 1061-1069
        • Nitz U.A.
        • Gluz O.
        • Kümmel S.
        • et al.
        Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2- early breast cancer.
        J Clin Oncol. 2022; 40: 2557-2567